Methods and compositions for modulating angiogenesis

Details Methods and compositions for modulating angiogenesis Methods and compositions for modulating angiogenesis

2008-01-29

2008-01-29

McGarry, Sean (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

C514S002600, C435S006120, C435S007100, C435S377000

Reexamination Certificate

active

07323439

ABSTRACT:
Methods and compositions for modulating angiogenesis in a host are provided. In the subject methods, an effective amount of Ca2+/calcineurin/NF-ATc signaling pathway modulatory agent is administered to the host. In many embodiments, the Ca2+/calcineurin/NF-ATc signaling pathway modulatory agent is an NF-ATc antagonist, e.g., in those embodiments of inhibiting angiogenesis. The subject methods find use in a variety of different applications, including the inhibition of tumor growth and the treatment of disease conditions characterized by tumor presence. Also provided are methods of screening for agents that inhibit angiogenesis by modulating the Ca2+/calcineurin/NF-ATc signaling pathway.

REFERENCES:
patent: 6096515 (2000-08-01), Crabtree et al.
patent: WO 00/30671 (2000-06-01), None
Hernandez et al. “Selective Inhibition of Vascular Endothelial Growth Factor-mediated Angioenesis by Cycloporin A; Roles of the Nuclear Factor of Activated T Cells and Cyclooxygenase 2”J. Exp Med., vol. 193, No. 5, Mar. 5, 2001 pp. 607-620.
Folkman et al “Angiogenesis”The Journal of Biological Chemistry, vol. 267, No. 16, Issue of Jun. 5, pp. 10931-10934, 1992.
Clipstone et al. “Identification of calcinerurin as a key signaling enzyme in T-lymphocyte activation”Nature, vol. 357, Jun. 25, 1992, pp. 695-697.
Flanagan et al, “Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A”Nature, vol. 352 Aug. 29 1991 pp. 803-807.
Emmel et al. “Cyclosproin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation”Science, vol. 246, Dec. 22, 1989 pp. 1617-1620.
Shaw et al, “Identification of a Putative Regulator of Early T Cell Activation Genes”Science, vol. 241, Jul. 8, 1988 pp. 202-205.
Durand et al. “A 275 Basepair fragment at the 5′ end of the interleukin 2 gene enhances expression from a heterologous promoter in response to signals from the L cell antigen receptor”J. Exp. MedThe Rockefeller University Press , col. 165, Feb. 19871 pp. 395-407.
Durand et al, “Characterization of Antigen Receptor Respone Elemetns within the Interleukin-2 Enhancer”,Molecular and Cellular Biology, Apr. 1988, 0.1715-1724.
Bolontrade et al. “Angiogenesis is an early event in the development of chemically induced skin tumors”Carcinogenesis, vol. 19 No. 12 pp. 2107-2113, 1998.
Jiang et al. “Anti-tumor-promoting action of FK506, a potent immunosuppressive agent”Carcinogenesis, Jan. 1993, vol. 14, pp. 67-71.
Ranger et al. “The transcription factor NF-Atc is essential for cardiac valve Formation”Nature, Mar. 1998, vol. 392, pp. 186-190.
Luis Armesilla et al. “Vascular endothelial growth factor activated nuclear factor of activated T Cells in human endothelial cells: a role for tissue factor gene expression”Mol. Cell. Biol. Mar. 1999, vol. 19, No. 3, pp. 2023-2043.

Affiliated with

Also associated with

Rating

Methods and compositions for modulating angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for modulating angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for modulating angiogenesis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2796595